



Richard Davies appointed CEO at Auregen BioTherapeutics

Gurnet Point Capital, the Bertarelli family's closed healthcare fund, is the majority shareholder of Auregen, which is based in Geneva and has facilities in Zurich and the US.

Geneva, Switzerland, November 20th 2018 ... Auregen BioTherapeutics, a rare disease cell therapy company, today announced the appointment of Richard Davies as CEO. The company is headquartered in Geneva, Switzerland, with facilities in Zurich and a USA subsidiary based in Cambridge, Massachusetts. Auregen's lead investor is Gurnet Point Capital, the Bertarelli family's closed healthcare fund.

Auregen BioTherapeutics applies innovative 3D biofabrication technologies to tissue engineering and regenerative medicine. Auregen is pioneering 3D bioprinting through an intellectual property platform which includes exclusive licenses from academic institutions, such as the Swiss Federal Institute of Technology in Zurich (ETH Zurich). The company's initial clinical focus is to create new treatment options for patients with rare congenital craniofacial disorders.

The new CEO Richard Davies brings over 27 years of Life Sciences industry experience to Auregen BioTherapeutics. He previously spent three years as CEO of Bonesupport AB, which increased sales by over 50% under his leadership. Richard. Davies was awarded European Medtec CEO of the year for 2017. Prior to Bonesupport AB, Mr. Davies served as Chief Commercial Officer of Hospira Inc., a global pharmaceutical company which was acquired by Pfizer in 2015 for \$17B.

Earlier in his career, Mr. Davies spent nine years in increasingly senior leadership positions at Amgen including global positions within Europe, Australia and the US, also at one point leading Amgen's business units in Latin America and Asia. He began his pharmaceutical career at Eli Lilly and holds a Bachelor's degree in Applied Chemistry from Portsmouth University and an MBA from Warwick Business School.

Travis Wilson, a Partner at Gurnet Point Capital and the Chairman of Auregen, commented: "Auregen BioTherapeutics has reached an inflection with its lead rare disease program transitioning to the clinic. Our aim of helping patients with craniofacial disorders for which there are few treatment alternatives is coming into focus. With this patient-driven mission, there is a need for a deeply experienced CEO with a proven track record to develop and commercialise novel therapies for unmet medical needs. In Richard, we more than have that person."

---ENDS---

About Gurnet Point Capital

Gurnet Point Capital is a unique healthcare fund founded by Ernesto Bertarelli and led by Christopher Viehbacher who, together, have decades of expertise in an industry for which they share a passion, both as Chief Executives and as investors. With an initial allocation of \$2 billion, Gurnet Point Capital is investing long-term capital and supporting entrepreneurs in building a new generation of companies. Based in Cambridge MA, USA, its remit is global, encompassing life sciences and medical technologies. The fund invests across all stages of product development through to commercialization and does so with an approach that is a hybrid of venture and private equity investing strategies.

www.gurnetpointcapital.com

For further information, please contact
Hirzel.Neef.Schmid.Counselors
Marie-Hélène Hancock
+41 79 204 21 22
marie-helene.hancock@konsulenten.ch